Gastroenteropancreatic Neuroendocrine Carcinoma
📧 Sign up to get email alerts when something new happens for Gastroenteropancreatic Neuroendocrine Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) [Phase 2]
Phase 2 trial evaluating nivolumab with or without ipilimumab in patients with advanced, refractory pulmonary or gastroenteropancreatic poor…
-
CLINICAL_TRIALS trial_result · 2019-12-30Clinical Trial Update: Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes [Phase 2]
Phase II study of avelumab as second-line treatment for metastatic gastroenteropancreatic neuroendocrine carcinoma (WHO Grade 3) afteretopos…
-
CLINICAL_TRIALS trial_result · 2019-12-19Clinical Trial Update: Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) [Phase 2]
Phase 2 trial investigating everolimus with temozolomide in advanced gastroenteropancreatic neuroendocrine carcinoma (G3) has completed.